Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025)

Mineralys Therapeutics (MLYS) reported Capital Expenditures of $15000.0 for Q4 2025, down 59.46% sequentially from $37000.0 in Q3 2024.

Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025) Analysis & Trends

Mineralys Therapeutics (MLYS) has 2 years of Capital Expenditures data on file, last reported at $15000.0 in Q4 2025.

For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to $15000.0; the trailing twelve-month figure through Dec 2025 stood at $15000.0 (down 84.38% YoY), and the FY2025 full-year result was $15000.0, down 84.38% from the prior year.
Capital Expenditures slipped to $15000.0 in Q4 2025, from $37000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $59000.0 in Q1 2024 to a low of $15000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Mineralys Therapeutics	2.24 Bn	2.24 Bn	-	-

Download Data